Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
07:00am, Wednesday, 28'th May 2025
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metab
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect
10:00am, Thursday, 22'nd May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments
03:25pm, Wednesday, 21'st May 2025
Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis, with positive 96-week phase 2b data published in NEJM. The SYNCHRONY phase 3 program targets a broad
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation
10:00am, Tuesday, 20'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect
10:00am, Thursday, 15'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
Best Biotech Stocks to Buy in 2025
08:10am, Tuesday, 13'th May 2025
The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector.
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
07:00am, Monday, 12'th May 2025
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX)
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
07:11am, Friday, 09'th May 2025
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at
